Product
Rabinizumab
1 clinical trial
1 indication
Indication
Age-Related Macular DegenerationClinical trial
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) PatientsStatus: Recruiting, Estimated PCD: 2024-03-01